Recent changes
GovPing tracks this category across sources from 104 outlets, representing a portion of the 2,344 sources on GovPing, covering guidance, enforcement, rule, notice, and consultation instruments. In the past 7 days, 608 changes have been recorded.
Recent urgent actions include FDA's Class I recall of Draeger Atlan A350 anesthesia workstations for potential piston ventilator failure and a Good Brain Tonic recall after botulism contamination was identified. Health Canada also issued a Revolution Ascend CT recall for a security vulnerability, and FDA pulled Morovan nail polish remover (4,000 units) for prohibited methylene chloride.
NY Clarifies Clinical Lab Personnel Requirements for Glucometry
The New York State Department of Health has issued guidance clarifying clinical laboratory personnel requirements, specifically regarding nurses performing high-complexity glucometer testing. This clarification aligns with recent federal CMS interpretations and will be enforced by the NY Clinical Laboratory Evaluation Program.
California Board of Pharmacy News Roundup - August 2025
The California Board of Pharmacy issued a news roundup for August 2025, providing updates on Rite Aid closures, emergency refills, medication error reporting requirements effective September 1, 2025, and a new online portal for drug theft/loss reporting. A new Pharmacist-in-Charge training webinar is also available.
California Board of Pharmacy: Vaccine Administration Update
The California Board of Pharmacy issued a news roundup detailing changes to pharmacist authority regarding vaccine administration, effective January 1, 2026, due to Assembly Bill 1503. The update encourages pharmacists to transition to a standard of care practice model for immunizations for patients three years and older.
California Board of Pharmacy December Update: Standard of Care, Vaccines, CAMER
The California Board of Pharmacy's December 2025 update announces the transition of certain pharmacist-provided patient care services, including vaccine administration, to a standard of care model effective January 1, 2026, per AB 1503. It also reminds schools about standing orders for albuterol and epinephrine and mandates reporting medication errors to the CAMER system for events on or after September 1, 2025.
California Board of Pharmacy Updates and AB 1503 Changes
The California Board of Pharmacy is updating its regulations effective January 1, 2026, due to Assembly Bill 1503. Key changes include a transition to a Standard of Care practice model for certain pharmacist-provided services and new requirements for nonresident pharmacies operating in California, effective July 1, 2026.
California Board of Pharmacy Updates on SCRA, AB 1503, and Nonresident Pharmacies
The California Board of Pharmacy issued a news roundup detailing updates on the Servicemembers Civil Relief Act (SCRA), Assembly Bill 1503 impacting pharmacist practice, and new requirements for nonresident pharmacies. Key changes include the transition of certain pharmacist-provided patient care services to a standard of care model and new PIC designation rules for out-of-state pharmacies operating in California.
FDA Requests Removal of Suicidal Behavior Warning from GLP-1 RA Medications
The FDA is requesting that drug manufacturers remove the warning about suicidal ideation and behavior from the labeling of GLP-1 RA medications approved for weight reduction. This action follows a comprehensive review that found no increased risk associated with these drugs.
MHRA Medical Devices Exceptional Use Authorisations List Updated
The UK's MHRA has updated its list of medical devices granted exceptional use authorisations. This guidance document provides transparency on manufacturers and devices that have received exemptions, including those whose authorisations have expired or been cancelled.
MHRA: Stop using non-sterile alcohol-free wipes due to infection risk
The MHRA and UKHSA are advising the public not to use four specific non-sterile alcohol-free wipe products due to contamination with Burkholderia stabilis bacteria. These products have been withdrawn from sale, but may still be in homes, and are linked to 59 cases, including one death.
MHRA: Quetiapine Oral Suspension Recalled Due to Incorrect Active Ingredient
The MHRA has issued a recall for all batches of quetiapine oral suspension manufactured by Eaststone Limited due to an incorrect amount of the active ingredient, potentially leading to overdose. Approximately 166 bottles manufactured between October 2025 and January 2026 are affected. Patients are advised not to stop medication without consulting a healthcare professional.
Get daily alerts for pharma & drug safety
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
606 changes in last 7 days
Latest high priority updates
Browse Categories
104 official sources tracked
Get Pharma & Drug Safety alerts
Daily digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get Pharma & Drug Safety alerts
We'll email you when new pharma & drug safety changes are detected.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.